Google
NAMSW Stock Price & Analysis — Newamsterdam Pharma Company N.V. Warrant
NAMSW FAQ
What is NAMSW's ROE?
Newamsterdam Pharma Company N.V. Warrant reports a Return on Equity (ROE) of -31.98%.
What is NAMSW's dividend yield?
Newamsterdam Pharma Company N.V. Warrant offers a dividend yield of 0.00%.
What is NAMSW's Quality Score?
Our AI rates NAMSW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NAMSW?
Our AI Timing Score for NAMSW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
NAMSW AI Analysis Summary
Our AI summary for NAMSW: Newamsterdam Pharma Company N.V. Warrant (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of -31.98%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.00
Price
1.00
(6.67%)
Day Change
|
|
|---|
NAMSW, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.00 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
0.02 M
GREAT
|
| Average 1W Daily Value |
9231.808000000000
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Phone: 31 35 206 2971
Website: https://www.newamsterdampharma.com
Employees: 100
Sector: -
Description: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
